

## Disclosures

### Personal Commercial (18)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Baron and Bud	Other - Expert Witness	Significant (>= \$5,000)	General Cardiology
Bayer	Consultant Fees/Honoraria	Significant (>= \$5,000)	Other
Bayer Healthcare Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
BMS	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Cleveland Clinic	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Eli Lilly and Company	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Haemonetics	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Hikari Dx	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Idorsia	Research/Research Grants	Significant (>= \$5,000)	Acute Coronary Syndromes
Instrumentation Labs	Research/Research Grants	Significant (>= \$5,000)	
LabCorp Drug Development	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Medforce	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Novartis Corporation	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Prolocor	Research/Research Grants	Modest (< \$5,000)	Acute Coronary Syndromes
Recor	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Recor Medical	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Web MD Medscape	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Wolters Kluwer	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
<b>Self</b>				
2019	Clopidogrel	Third Party	Clopidogrel	Significant (>= \$5,000)

<sup>†</sup> Commercial Funding Source | <sup>#</sup> Trial Name

## Agreement

**Certified Education Attestation** | Signed on 6/17/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

**Confidentiality, Disclosure and Assignment Agreement** | Signed on 6/17/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

**Embargo** | Signed on 6/17/2025

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

**On-Going Obligation Agreement** | Signed on 7/21/2025

---

## **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.